Developing and Testing a Cost-Assessment Tool for Cancer Screening Programs

American Journal of Preventive Medicine

Volumn 37, Issue 3, 2009, Pages 242-247

  Subramanian, Sujha ^a   Ekwueme, Donatus U ^b   Gardner, James G ^b   Trogdon, Justin ^a  

^a RTI INTERNATIONAL   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SCREENING; CASE MANAGEMENT; COST; COST EFFECTIVENESS ANALYSIS; DATA BASE; HEALTH CARE COST; HUMAN; STANDARDIZATION;

BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HEALTH CARE COSTS; HUMANS; MASS SCREENING; PILOT PROJECTS; PROGRAM EVALUATION; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 68149089747     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amepre.2009.06.002     Document Type: Article

References (30)

1. Frazier A.L., Colditz G.A., Fuchs C.S., and Kuntz K.M. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 284 (2000) 1954-1961
2. Vijan S., Hwang E.W., Hofer T.P., and Hayward R.A. Which colon cancer screening test?. A comparison of costs, effectiveness, and compliance. Am J Med 111 (2001) 593-601
3. Pickhardt P.J., Hassan C., Laghi A., Zullo A., Kim D.H., and Morini S. Cost-effectiveness of colorectal cancer screening with computed tomography colonography: the impact of not reporting diminutive lesions. Cancer 109 (2007) 2213-2221
4. Pignone M., Saha S., Hoerger T., Lohr K.N., Teutsch S., and Mandelblatt J. Challenges in systematic reviews of economic analyses. Ann Intern Med 142 12 Pt 2 (2005) 1073-1079
5. Loeve F., Brown M.L., Boer R., van Ballegooijen M., van Oortmarssen G.J., and Habbema J.D. Endoscopic colorectal cancer screening: a cost-saving analysis. J Natl Cancer Inst 92 (2000) 557-563
6. Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B.O., and Stoddart G.L. Methods for the economic evaluation of health programs (2005), Oxford University Press, Oxford
7. In: Gold M.R., Siegel J.E., Russel L.B., and Weinstein M.C. (Eds). Cost-effectiveness in health and medicine (1996), Oxford University Press, New York
8. Siegel J.E., Torrance G.W., Russell L.B., et al. Guidelines for pharmacoeconomic studies: recommendations from the Panel on Cost Effectiveness in Health and Medicine. Pharmacoeconomics 11 (1997) 159-168
9. Haycox A., and Walley T. Pharmacoeconomic: evaluating the evaluators. Br J Clim Pharmacol 43 (1997) 451-456
10. Drummond M.F., Brandt A., Luce B.R., et al. Standardizing methodologies for economic evaluation in health care. Int J Technol Assess Health Care 9 (1993) 26-36
11. Rovira J. Standardization of the economic evaluation of health technologies, European developments. Med Care 34 12S (1996) DS182-DS288
12. Jefferson T., and Demicheli V. Quality of economic evaluations in health care: it is time for action to ensure higher methodological quality. BMJ 324 (2002) 313-314
13. Eisenstein E.L., Ortiz M., Anstrom K.J., Crosslin D.R., and Lobach D.F. Assessing the quality of medical information technology economic evaluations: room for improvement. AMIA Annu Symp Proc (2006) 234-238
14. Rovithis D., and Liaropoulos L. The CHESME Health Economic Evaluations Database (CHESME HEED) project. Eur J Health Econ 9 (2008) 99-101
15. Tangka F.K., Subramanian S., Bapat B., et al. Cost of starting colorectal cancer screening programs: results from five federally funded demonstration programs. Prev Chronic Dis 5 (2008) A47
16. Subramanian S., Ekwueme D., Gardner J., Kramer C., Bapat B., and Tangka F. Identifying and controlling for program level differences in cost-effectiveness comparisons: lessons from the Evaluation of the National Breast and Cervical Cancer Screening Program (NBCCEDP). Eval Program Plann 31 (2008) 136-144
17. Legood R., Gray A.M., Mahé C., et al. Screening for cervical cancer in India: how much will it cost?. A trial based analysis of the cost per case detected. Int J Cancer 117 (2005) 981-987
18. Schweitzer M.E., French M.T., Ullmann S.G., and McCoy C.B. Cost-effectiveness of detecting breast cancer in lower socioeconomic status African American and Hispanic women through mobile mammography services. Med Care Res Rev 55 (1998) 99-115
19. Mansley E.C., Dunet D.O., May D.S., Chattopadhaya S.K., and McKenna M.T. Variations in average costs among federally-sponsored state-organized cancer detection programs: economics of scale?. Med Decis Making 22S (2002) S67-S79
20. Subramanian S., Sankaranarayan R., Bapat B., et al. Cost-effectiveness of screening for oral cancer: results from a cluster randomized controlled trial in India. Bull World Health Organ 87 (2009) 200-206
21. Ekwueme D., Gardner J., Subramanian S., et al. Cost analysis of the National Breast and Cervical Cancer Early Detection Program (NBCCEDP)-Selected States, 2003-2004. Cancer 112 (2008) 626-635
22. Anderson D.W., Bowland B.J., Cartwright W.S., and Bassin G. Service-level costing of drug abuse treatment. J Subst Abuse Treat 15 (1998) 201-211
23. French M.T., DunlapL J., Zarkin G.A., McGeary M.A., and McLellan A.T. A structured instrument for wqestimating the economic cost of drug abuse treatment: the Drug Abuse Treatment Cost Analysis Program (DATCAP). J Subst Abuse Treat 14 (1997) 1-11
24. Salomé H.J., French M.T., Miller M., and McLellan A.T. Estimating the client costs of addiction treatment: first findings from the Client Drug Abuse Treatment Cost Analysis Program (Client DATCAP). Drug Alcohol Depend 71 (2003) 195-198
25. Ryerson A.B., Bernard V.B., and Major A.C. National Breast and Cervical Cancer Early Detection Program: 1991-2002 National Report (2005), USDHHS, CDC, Atlanta. www.cdc.gov/cancer/NBCCEDP/bccpdfs/national_report.pdf
26. CDC. The National Breast and Cervical Cancer Early Detection Program. www.cdc.gov/cancer/nbccedp/about.htm
27. Eheman C.R., Benard V.B., Blackman D., et al. Breast cancer screening among low-income or uninsured women: results from the National Breast and Cervical Cancer Early Detection Program, July 1995 to March 2002 (United States). Cancer Causes Control 17 (2006) 29-38
28. Zarkin G.A., Dunlap L.J., and Homsi G. The Substance Abuse Services Cost Analysis Program (SASCAP): a new method for estimating drug treatment services costs. Eval Program Plann 27 (2004) 35-43
29. French M.T., Salome H.J., and Carney M. Using the DATCAP and ASI to estimate the costs and benefits of residential addiction treatment in the State of Washington. Soc Sci Med 55 (2002) 2267-2282
30. Zarkin G.A., Dunlap L.J., Wedehase B., and Cowell A.J. The effect of alternative staff time data collection methods on drug treatment service cost estimates. Eval Program Plann 31 (2008) 427-435